
---
title: '凯莱英：子公司凯莱英生物发展拟引入外部投资者'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=6128'
author: 证券时报网
comments: false
date: Fri, 25 Mar 2022 19:10:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=6128'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" style="color: #2f67d1;text-decoration: none;" code="002821" target="_blank">凯莱英</a>(002821)3月25日晚间公告，公司拟与海河<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" style="color: #2f67d1;text-decoration: none;" code="002821" target="_blank">凯莱英</a>基金、高瓴祈睿等签署投资协议，各投资方在<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" style="color: #2f67d1;text-decoration: none;" code="002821" target="_blank">凯莱英</a>生物发展完成对<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" style="color: #2f67d1;text-decoration: none;" code="002821" target="_blank">凯莱英</a>生物的全资收购后，对<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" style="color: #2f67d1;text-decoration: none;" code="002821" target="_blank">凯莱英</a>生物发展进行投资并认购其新增注册资本。各投资方将按照投资协议约定分期向<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" style="color: #2f67d1;text-decoration: none;" code="002821" target="_blank">凯莱英</a>生物发展合计增资不超过约25.34亿元。<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" style="color: #2f67d1;text-decoration: none;" code="002821" target="_blank">凯莱英</a>生物发展未来将定位成为<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SZ002821" style="color: #2f67d1;text-decoration: none;" code="002821" target="_blank">凯莱英</a>医药集团中包括大分子药物、抗体偶联药物、细胞基因治疗药物以及mRNA药物等在内的独家合同研发生产服务（CDMO）企业。</p>

                  
</div>
            